BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ:CELG) announced that data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with relapsed chronic lymphocytic leukaemia (CLL) were presented during the 51st American Society of Hematology annual meeting in New Orleans, LA. The phase II study conducted at MD Anderson Cancer Center demonstrated a 64 percent overall response after 12 cycles, including the observation of complete responses.
